Scarica l'app Stockscreener
4.511
0.13%
0.021
Precedente Chiudi:
$4.49
Aprire:
$4.49
Volume 24 ore:
14,215
Relative Volume:
0.01
Capitalizzazione di mercato:
$1.30B
Reddito:
$9.77M
Utile/perdita netta:
$-109.00M
Rapporto P/E:
-12.52
EPS:
-0.3604
Flusso di cassa netto:
$-93.83M
1 W Prestazione:
-3.31%
1M Prestazione:
+0.13%
6M Prestazione:
-10.97%
1 anno Prestazione:
+261.12%
Intervallo 1D:
$4.475
$4.51
Intervallo di 1 settimana:
$4.335
$4.78
Portata 52W:
$1.13
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Nome
Taysha Gene Therapies Inc
Settore
Industria
Telefono
(214) 612-0000
Indirizzo
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.51 | 1.29B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
435.03 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.95 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.99 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.52 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-21 | Iniziato | Raymond James | Strong Buy |
| 2025-07-11 | Iniziato | BofA Securities | Buy |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-04-09 | Iniziato | Piper Sandler | Overweight |
| 2023-02-01 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-03-09 | Iniziato | Robert W. Baird | Outperform |
| 2022-03-01 | Iniziato | Wells Fargo | Overweight |
| 2022-02-18 | Iniziato | SMBC Nikko | Outperform |
| 2021-12-16 | Iniziato | Guggenheim | Buy |
| 2021-07-16 | Iniziato | Needham | Buy |
| 2021-06-24 | Iniziato | Truist | Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-06-09 | Iniziato | Wedbush | Outperform |
| 2021-06-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-05-11 | Ripresa | Jefferies | Buy |
| 2021-02-24 | Iniziato | William Blair | Outperform |
| 2021-01-05 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Chardan Capital Markets | Buy |
| 2020-10-19 | Iniziato | Goldman | Buy |
| 2020-10-19 | Iniziato | Jefferies | Buy |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
Taysha Gene Therapies (TSHA) making progress on crucial Rett syndrome treatment - MSN
Taysha Gene Therapies (NASDAQ: TSHA) insider selling 200,000 shares - Stock Titan
Taysha Gene Therapies (TSHA) Price Target Increased by 12.72% to 9.96 - MSN
Aug Mood: Does Taysha Gene Therapies Inc have strong fundamentals2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn
Aug Mood: Whats the fair value of Taysha Gene Therapies Inc stock2026 Spike Watch & Consistent Return Investment Signals - baoquankhu1.vn
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 earnings call transcript - MSN
Taysha Gene Therapies (TSHA) Making Progress on Crucial Rett Syndrome Treatment - Yahoo Finance
Taysha Gene Therapies (NASDAQ:TSHA) Shares Up 6.9% on Analyst Upgrade - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00 - MarketBeat
CCORF Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Canaccord raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com South Africa
Canaccord raises Taysha Gene Therapies price target on trial progress - Investing.com
Capricorn Fund Managers Ltd Makes New Investment in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
5 Best Multibagger Penny Stocks to Invest In - Insider Monkey
Citizens Maintains Taysha Gene Therapies (TSHA) Market Outperform Recommendation - MSN
Taysha Gene Therapies upgraded at Goldman Sachs on advancing Rett syndrome asset - MSN
Aug Patterns: Is Taysha Gene Therapies Inc undervalued by DCF analysis2026 Institutional & Reliable Price Breakout Alerts - baoquankhu1.vn
TSHA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SG Americas Securities LLC Acquires 748,525 Shares of Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Hennion & Walsh Asset Management Inc. Invests $1.70 Million in Taysha Gene Therapies, Inc. $TSHA - MarketBeat
Should you avoid Taysha Gene Therapies Inc stock right nowProfit Target & Weekly Top Gainers Trade List - baoquankhu1.vn
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
Buybacks Report: Is Taysha Gene Therapies Inc undervalued by DCF analysisQuarterly Investment Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Catalysts: Will Taysha Gene Therapies Inc benefit from AI trendsJobs Report & Verified Momentum Stock Alerts - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Truist Financial - MarketBeat
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha Gene Therapies FY 2025 earnings preview - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
BMO Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA) - The Globe and Mail
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies Inc Azioni (TSHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.62%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):